Latvian pharmaceutical manufacturer JSC Olpha continues to expand its presence in international markets, starting its first deliveries to Latin American countries. At the end of 2025, the company won a Mexican government tender for the supply of prescription drugs to hospitals for lowering high cholesterol levels. The first delivery of medicines to Mexico took place in December 2025.
In accordance with the terms of the public tender, JSC Olpha will supply specific medicines to Mexican hospitals until the end of 2026. With this successful procurement result, Olpha will continue to develop its exports in the Latin American and Caribbean region, which is home to approximately 670 million people.
“Winning this international tender is a significant step in the implementation of Olpha’s strategic plans, which envisage a significant expansion of its presence in Western European and other global markets. At the same time, this is also confirmation that a small Latvian pharmaceutical manufacturer is able to compete with multi-billion-dollar pharmaceutical giants in the global market. Winning a tender of this level and successfully completing the first deliveries of medicines to the South American continent is a clear signal that the Latvian pharmaceutical industry can and should effectively use its potential for economic development,” emphasizes Juris Bundulis, Chairman of the Board of AS Olpha.
In 2025, AS Olpha also participated in several public procurements organized by European Union countries. In December last year, Olpha won a tender announced by the Italian region of Merkes for the supply of anticoagulants to state hospitals. The company is also participating in other public procurement tenders in Italy and other EU countries.
It should be noted that following a change in shareholders, which was completed at the end of 2021, Olpha is developing its product portfolio with more than 50 new off-patent drugs, seven of which have already been commercialized in EU markets in therapeutic groups such as cardiology, oncology, anti-diabetic drugs, and others. It is planned that by 2026, upon completion of registrations and fulfilment of other drug market regulatory requirements, up to 20 new drugs from Olpha’s new product portfolio will enter the drug markets of various countries.
About Olpha
AS Olpha (formerly Olainfarm) is one of the largest companies in the Baltic States with 50 years of experience in the manufacture of medicines and other pharmaceutical products. The company's product range is constantly evolving and expanding, currently including more than 70 finished dosage forms and more than 20 active pharmaceutical ingredients. The main therapeutic groups include neurology, cardiology, antibacterial therapy, oncology, urology, as well as medicines for the treatment of allergies and diabetes. AS Olpha products are exported to more than 60 countries. The company employs more than 700 people. AS Olpha has subsidiaries in Italy, Spain, Germany, and Poland.
Please enter your username and password.
2026 © The Baltic Times /Cookies Policy Privacy Policy
